Scilex Holding Co
Close on Oct 19, 2026
- Market cap
- $17.71M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2024 Ended Sep 30, 2024 | Oct 8, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 1, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 16, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 2, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Dec 1, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Jul 5, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | Apr 3, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Jan 3, 2023 | Before market open | – | – | – |
Press releases
Announcements Scilex filed with the SEC
Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Dear Scilex Holding Company Stockholders and other holders of Scilex Holding Company Securities:
Other events · EX-99.1 to Form 8-K
Form of Scilex Holding Company Opt-In Agreement
Other events · EX-99.2 to Form 8-K
Onboarding Documentation - Datavault AI Wallet Creation
Other events · EX-99.3 to Form 8-K
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Daniel A. Saunders (SBN 161051)
Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from DataVault AI
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
Scilex Holding Company Announces Signing of a Securities Purchase Agreement with an Institutional Investor to Exchange $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held By Scilex Holding Company for $200 Million in Bitcoin
Material agreement · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Capitalized terms used but not otherwise defined in this Exhibit 99.2, shall have their respective meanings as set forth in the Form 8-K to which this Exhibit is attached.
Material agreement · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
For more information on Scilex Holding Company, refer to www.scilexholding.com
Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule
Other events · EX-99.1 to Form 8-K
For more information on Scilex Holding Company, refer to www.scilexholding.com
Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Announces 1-for-35 Reverse Stock Split
Regulation FD disclosure · EX-99.1 to Form 8-K
For more information on Scilex Holding Company, refer to www.scilexholding.com
Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024
Other events · EX-99.1 to Form 8-K
Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)
Other events · EX-99.2 to Form 8-K
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock
Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Announces $17 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering
Material agreement · Other events · EX-99.2 to Form 8-K
The joint venture, Scilex Bio (“Scilex Bio JV”), will have global development and commercialization rights for a Phase 2 clinical stage, potential best-in-class novel oral tablet, KDS2010, for the treatment of obesity and neurodegenerative diseases including Alzheimer’s disease.
Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Announces Receipt of Notice from Nasdaq
Listing notice · Other events · EX-99.1 to Form 8-K
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a
Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024
Results of operations · EX-99.1 to Form 8-K
Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to
Material agreement · Agreement terminated · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing
Material agreement · Agreement terminated · New financial obligation · Regulation FD disclosure · EX-99.2 to Form 8-K
Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan
Material agreement · Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq:
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024
Results of operations · EX-99.1 to Form 8-K
Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.
Executive or director change · Other events · EX-99.1 to Form 8-K
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024
Results of operations · EX-99.1 to Form 8-K
Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory
Regulation FD disclosure · EX-99.1 to Form 8-K